Olichon, A
It would therefore be wonderful to see at least some of the 60+ pharma companies developing drugs in the obesity space to consider flexible personalised dosing treatment arms like the one proposed above
Praise for Becky Dorner & Associates GLP-1 Therapy for Patients with Obesity: Identifying Solutions to Optimize Nutrition Aimee Shea, MPH, RDN, CCMS, LD Aimee Shea, MPH, RDN, CCMS, LD The Eating Disorder Guidebook Self Study Course Emma Fogt, EdD, MBA, RDN, FAND Guidance for Evaluation and Management of GERD- Short Course Emma Fogt, MBA, MS, RDN, FAND Food Code 2022 Course Marcy Cook, RDN, LD The Dietitians Guide to Nutrition Assessment Course Jamie Smith, MS, RD, CSG, LDN
Less commonly, Ozempic has been linked to vision changes
(can be combined with a mass gainer or pure carb)